Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | +2.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.18 | N/A | +2.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the advancements made in their pipeline. They emphasized their commitment to executing strategic initiatives.
We are pleased with our progress in advancing our pipeline.
Our focus remains on executing our strategic initiatives.
IDEAYA Biosciences reported a narrower-than-expected loss per share, which is a positive sign for investors. However, the stock still fell by 1.6% in reaction to the earnings report. The lack of revenue data and forward guidance may have contributed to the stock's decline, as investors often look for clearer future expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADOBE INC
Mar 23, 2021